Bitopertin, a GlyT1 inhibitor, attenuates the development of dyskinesia in the 6-OHDA-lesioned rat
Objective: To evaluate the effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin at preventing dyskinesia development in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s…Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series
Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…Amelioration of Levodopa-induced Dyskinesias using Genetic Silencing of Striatal CaV1.3 in Parkinsonian Rats: Impact of Sex and Advancing Age
Objective: To advance understanding of striatal CaV1.3 (cacna1d) channel silencing as a therapeutic approach to reduce levodopa-induced dyskinesias (LID), a side effect of long-term escalating…The effect of levodopa on speech in patients with Parkinson’s disease
Objective: To assess levodopa-induced changes in fMRI signal in areas involved in speech production (ROIs) in PD. Evaluate association between these changes and changes in…Patient and caregiver satisfaction of video-assisted telenursing in patients treated with LCIG
Objective: To evaluate the feasibility and patient satisfaction of video-assisted telenursing as well as demonstrate resolution for treatment-related issues in the real-word levodopa-carbidopa intestinal gel…Natural progression of patients with Parkinson disease on less pulsatile levodopa therapy
Objective: To evaluate the natural progression of Parkinson disease (PD) in patients on less pulsatile levodopa therapy (LPT). Background: Previously we have shown that patients…Comparing duodenal levodopa infusion based on length of treatment in advanced Parkinson’s.
Objective: In this study we seek to compare characteristics and complications of patients suffering from advanced Parkinson's treated with duodenal levodopa infusion. Background: Motor fluctuations…Heart rate variability is affected by standing and medication intake in Parkinson’s disease
Objective: To evaluate the effect of levodopa and orthostatism on heart rate variability (HRV) in a sample of consecutive subjects with Parkinson's disease (PD). Background:…Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias
Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…Subgroup analyses by Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) of patients treated with levodopa inhalation powder 84mg or placebo to treat OFF symptoms in patients with Parkinson’s disease (PD)
Objective: An analysis of the proportion of patients who turned ON after levodopa inhalation powder (CVT-301) 84mg treatment vs placebo, compared across subgroups of patients…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 57
- Next Page »